News
IDIBELL gains presence in the list of scientists with the highest impact in the world: four more than last year
The Stanford University Top 2% of Scientists, which includes the most impactful scientists of the world, includes this year 34 IDIBELL researchers, of which three reaffirm their position among the top 10 in Spain and four have first entered.
IDIBELL receives funding from the US National Institutes of Health to advance neural regeneration
The Northwestern University (Chicago), IDIBELL and IBEC were awarded a NIH project that will help develop new treatments for spinal cord injuries and other neurodegenerative pathologies.
Four IDIBELL researchers receive funding from the CaixaImpulse 2024 call
Pablo Naval, Laura Costas, Josep M. Aran and Antonella Consiglio will develop their research and innovation projects within the framework of this call.
Foods such as oily fish or potatoes influence gene expression in the colon
More studies would open new paths contributing to the prevention of gastrointestinal conditions such as colorectal cancer or inflammatory bowel diseases through diet.
B-ACTIVE: serious games platform to promote healthy behavior in people with cancer
Paula Jakszyn (IDIBELL & ICO) and Dr. Jordi Vilaró (URL) team has been chosen to develop a serious game that promotes physical activity in patients with chronic pathologies.
Bellvitge leads the creation of a new, more precise tool to assess chemotherapy-induced neurological toxicity
IDIBELL, HUB and ICO have led a European study that presents an innovative tool to assess chemotherapy-induced peripheral neuropathy (CIPN). The great advantage of this system is that it incorporates the patient’s perception, an aspect that until now medical scales did not adequately take into account.
A new personalized therapy through genomic profiling may improve survival in patients with cancer of unknown primary
The CUPISCO study, the largest to date on cancer of unknown primary, reveals that molecularly guided therapy is more effective than standard chemotherapy in cancer cases with an unfavorable prognosis.
Iron accumulation and cellular senescence in liver fibrosis: new perspectives on treatment
Researchers from IDIBELL, CIC bioGUNE, CIBEREHD and IRB Barcelona demonstrate that iron accumulation is an important factor in the progression of liver fibrosis and cellular senescence. The study suggests that the administration of iron chelators could be an effective strategy to slow down or prevent liver fibrosis.
Advances in chemical biology are fueled by multidisciplinarity and teamwork
Dr Albert Antolin from IDIBELL and ICO highlights the relevance of multidisciplinarity and teamwork for the advance of chemical biology research, a field that is opening new paths in drug discovery and precision medicine.